Prolactin testing helps clinicians identify the underlying cause of secondary hypogonadism, evaluate pituitary function, and guide necessary diagnostic imaging in men with low testosterone.
Most people assume that low testosterone is always a problem rooted directly in the testes or an inevitable consequence of aging. When a blood test shows low androgen levels, the immediate instinct is often to focus exclusively on replacing testosterone. Yet looking only at the gonads misses a fundamental truth of human endocrinology: testosterone production is driven and regulated by the brain.
When testosterone drops, the master control centers in the brain should respond by sending stronger chemical signals downward. When those signals remain flat or suppressed, the root cause lies higher up in the hypothalamic-pituitary axis. Prolactin testing provides a targeted window into this central control system. Understanding how prolactin interacts with testosterone helps men and their doctors identify treatable underlying conditions rather than jumping to lifelong hormone replacement prematurely.
This guide provides educational information about hormone testing and endocrinology. It does not provide medical diagnoses, treatment protocols, or personalized clinical advice. Anyone experiencing symptoms of hormone deficiency or receiving abnormal laboratory results should review their case with a qualified medical professional.
Prolactin is a peptide hormone produced by the lactotroph cells of the anterior pituitary gland. While widely known for its role in lactation and breast tissue development in women, prolactin is present and active in men as well. In healthy male physiology, prolactin circulates at relatively low concentrations and participates in immune function, metabolic regulation, and reproductive behavior.
Problems arise when prolactin levels rise above the standard physiological range. When circulating prolactin becomes persistently high, a condition termed hyperprolactinemia, it disrupts normal male reproductive signaling. Specifically, excess prolactin suppresses the pulsatile secretion of gonadotropin-releasing hormone from the hypothalamus. Without regular pulses of gonadotropin-releasing hormone, the pituitary gland cannot release adequate amounts of luteinizing hormone and follicle-stimulating hormone.
Luteinizing hormone is the primary biochemical signal that tells the Leydig cells in the testes to produce testosterone. When high prolactin suppresses luteinizing hormone release, the testes receive insufficient stimulation. The direct consequence is a secondary drop in total and free testosterone production. Follicle-stimulating hormone release is also impaired, which frequently leads to reduced sperm production and diminished fertility.
Measuring prolactin is not a tool to establish whether testosterone is low. Instead, it is an etiologic test designed to investigate why testosterone is low when the problem appears to originate in the brain. Prolactin acts as an explanatory biomarker rather than a general screening test.
To understand when prolactin testing matters, one must first understand how clinicians classify testosterone deficiency. The Endocrine Society recommends diagnosing male hypogonadism only when a patient exhibits consistent symptoms alongside unequivocally low morning testosterone levels. Once testosterone deficiency is confirmed, the next clinical objective is establishing whether the failure originates in the testes or the brain.
Clinicians make this distinction by measuring gonadotropins, specifically luteinizing hormone and follicle-stimulating hormone. This step separates hypogonadism into two distinct clinical categories:
Primary hypogonadism represents direct testicular failure. In this scenario, the testes cannot produce adequate testosterone despite receiving strong signals from the brain. Because testosterone is low, the normal negative feedback loop is broken. The pituitary gland responds by pumping out high amounts of luteinizing hormone and follicle-stimulating hormone to stimulate the testes. When lab work shows low testosterone paired with high gonadotropins, the condition is primary, and prolactin is rarely the underlying culprit.
Secondary hypogonadism represents central signaling failure. In this scenario, the testes are structurally capable of making testosterone, but the hypothalamus or pituitary fails to send the required hormonal signal. Here, testosterone is low, but luteinizing hormone is either low or unexpectedly normal.
A normal luteinizing hormone level in the presence of low testosterone is an abnormal physiological finding. Under healthy conditions, low testosterone should trigger a sharp increase in luteinizing hormone release. When luteinizing hormone remains within the standard reference range despite low testosterone, clinicians describe the result as inappropriately normal. This specific hormonal footprint points to hypothalamic or pituitary suppression, making testosterone testing and biomarkers such as prolactin clinically relevant.
Major clinical organizations agree on the physiological importance of prolactin, but their procedural guidelines recommend slightly different testing sequences. Understanding these recommendations helps clarify why a physician may or may not order a prolactin test immediately.
The American Urological Association provides clear, pattern-based guidance. The association recommends measuring serum prolactin specifically in patients who have confirmed low total testosterone accompanied by low or low-normal luteinizing hormone. Under this framework, prolactin is ordered as a targeted second-step test once central suppression is identified. The American Urological Association also recommends repeating any raised prolactin result to ensure the initial finding was not an artifact of collection stress.
The European Association of Urology outlines a complementary approach. Its guidelines suggest measuring luteinizing hormone alongside prolactin when pathological low testosterone is detected during initial evaluations. This combined initial assessment aims to rule out organic pituitary conditions early in the diagnostic process.
The Endocrine Society recommends evaluating secondary hypogonadism by measuring serum prolactin and transferrin saturation. This combined evaluation looks for both hyperprolactinemia and iron overload disorders such as hemochromatosis, both of which can suppress pituitary function.
Despite differences in testing timelines, all major guidelines share the same clinical logic. Prolactin testing is not a universal screening tool for every individual who feels fatigued. It is a targeted diagnostic test used to investigate the specific underlying causes of central hormonal feedback mechanisms and secondary testosterone deficiency.
A single high prolactin value does not automatically mean a patient has a pituitary tumor. Prolactin is a sensitive stress hormone that reacts to a wide array of non-pathological triggers. Clinicians must carefully evaluate potential confounders before reaching a definitive conclusion.
Physiological factors can cause temporary spikes in prolactin secretion. Acute psychological stress, physical exhaustion, intense exercise, and recent sexual activity can all raise circulating concentrations. Even the physical discomfort or anxiety of a blood draw can cause venipuncture-induced hyperprolactinemia. For this reason, laboratory protocols often recommend resting quietly before venipuncture to prevent transient, stress-related spikes.
Medications represent one of the most common causes of non-tumor hyperprolactinemia. Dopamine produced in the brain acts as the primary natural inhibitor of prolactin release. Any pharmaceutical agent that blocks dopamine receptors or depletes dopamine stores can cause prolactin levels to climb.
Several major medication classes frequently influence prolactin concentrations:
Systemic medical conditions also influence prolactin clearance and regulation. In primary hypothyroidism, low thyroid hormone levels prompt the hypothalamus to produce excess thyrotropin-releasing hormone. This excess thyrotropin-releasing hormone stimulates pituitary lactotrophs alongside thyroid-stimulating hormone, causing mild to moderate hyperprolactinemia. Similarly, chronic kidney disease impairs the clearance of prolactin, leading to elevated circulating levels. Liver cirrhosis can also alter normal steroid and peptide hormone metabolism.
Laboratory testing of prolactin involves complex immunoassay techniques. While modern assays are generally reliable, specific biochemical anomalies can generate misleading results that do not match the patient's actual clinical status.
One common source of confusion is macroprolactin. In healthy individuals, circulating prolactin consists primarily of a biologically active monomeric form with a molecular weight of 23 kilodaltons. In some individuals, prolactin molecules bind with immunoglobulin antibodies to form large complexes called macroprolactin, which have molecular weights exceeding 150 kilodaltons.
These massive molecular complexes are cleared very slowly from the bloodstream, causing them to accumulate. Standard laboratory assays detect macroprolactin and report a high total prolactin concentration. However, because macroprolactin is too large to cross blood vessel walls and interact with cellular receptors, it exerts little to no biological activity.
Patients with macroprolactinemia typically display no physical symptoms of hyperprolactinemia and maintain normal gonadotropin and testosterone levels. When a patient exhibits raised prolactin without matching clinical signs, the Endocrine Society suggests assessing for macroprolactin using polyethylene glycol precipitation. This laboratory technique strips away the large antibody complexes, allowing the lab to measure true monomeric prolactin.
Another rare but critical laboratory anomaly is the high-dose hook effect. This artifact occurs in two-site immunometric assays when circulating prolactin concentrations are extremely high, such as in patients with large pituitary macroprolactinomas. When vast amounts of prolactin saturate both the capture and signal antibodies independently, the assay fails to form the expected antibody sandwiches.
The resulting readout shows an artificially low or only mildly elevated prolactin level despite the presence of a massive tumor. If magnetic resonance imaging reveals a large pituitary mass exceeding one centimeter in diameter, but lab work reports only modest prolactin elevation, clinicians request serial sample dilutions. Diluting the serum sample 1 to 100 eliminates the saturation artifact and unmasks the true, massive prolactin concentration.
Because prolactin levels fluctuate in response to transient stress and minor daily variables, an initial abnormal result must never be treated as a definitive diagnosis. Clinical practice guidelines emphasize the necessity of verifying laboratory abnormalities before ordering extensive medical workups or initiating therapy.
The Endocrine Society hyperprolactinemia guideline notes that a single clearly elevated prolactin measurement can establish hyperprolactinemia if the sample was collected without excessive venipuncture stress. However, if any doubt exists regarding collection conditions or if the result is only modestly elevated, the test should be repeated on a separate day.
Guidelines from the American Urological Association and the American Society for Reproductive Medicine offer specific advice for mild elevations. When an initial prolactin result is raised but remains at or below 1.5 times the upper limit of normal, a repeat fasting measurement should be performed to rule out a spurious finding.
To obtain an accurate repeat measurement, clinicians often provide specific collection instructions:
Following these structured steps ensures that secondary investigations are built on accurate, reproducible hormonal data rather than transient laboratory noise.
When repeat testing confirms persistent, unexplained hyperprolactinemia, determining the anatomical cause becomes the primary clinical goal. Magnetic resonance imaging of the sella turcica, the bony structure housing the pituitary gland, is the gold standard imaging modality.
Pituitary adenomas are benign tumors classified based on their size and hormonal activity. Prolactin-secreting tumors, known as prolactinomas, represent the most common type of functioning pituitary adenoma. Microprolactinomas measure less than 10 millimeters in diameter, whereas macroprolactinomas measure 10 millimeters or larger.
The decision to perform pituitary imaging depends on the degree of prolactin elevation, the persistence of the finding, and the broader clinical picture:
When prolactin concentrations exceed 250 micrograms per liter (mcg/L) or nanograms per milliliter (ng/mL), a prolactinoma is highly probable. Values exceeding 500 mcg/L are considered diagnostic of macroprolactinomas. High concentrations that cannot be explained by medication or medical conditions warrant immediate pituitary magnetic resonance imaging with and without contrast.
When prolactin levels remain consistently elevated between the upper reference limit and 100 mcg/L on repeat testing, and non-tumor causes have been excluded, magnetic resonance imaging is generally indicated. This helps identify small microadenomas or other non-secreting mass lesions that compress the pituitary stalk.
Stalk compression, also known as the stalk effect, occurs when a non-functioning pituitary tumor or cyst presses against the infundibular stalk connecting the brain to the pituitary. This physical compression blocks the normal flow of dopamine from the hypothalamus to the pituitary gland. Without dopamine's natural inhibitory signal, normal lactotroph cells produce mild to moderate amounts of prolactin.
Pituitary imaging is not reserved exclusively for patients with elevated prolactin. The American Urological Association recommends that any man with confirmed total testosterone below 150 nanograms per deciliter (ng/dL) paired with low or low-normal luteinizing hormone undergo pituitary magnetic resonance imaging, regardless of his prolactin level.
This critical guideline exists because non-functioning pituitary adenomas, craniopharyngiomas, and infiltrative hypothalamic diseases can destroy gonadotropin-producing cells without producing prolactin. A completely normal prolactin result does not rule out structural pituitary pathology when secondary hypogonadism is severe.
Any patient presenting with secondary hypogonadism alongside neurological symptoms requires prompt neuroimaging. Symptoms of mass effect include persistent unexplained headaches, changes in peripheral vision, or progressive visual field defects caused by compression of the optic chiasm.
Endocrine evaluation relies on integrating symptoms, physical findings, and multiple lab values into a coherent clinical pattern. The following illustrative models show how the same laboratory marker can mean vastly different things depending on context.
A 38-year-old man presents with low libido, erectile dysfunction, and mild fatigue. His morning total testosterone is confirmed low at 190 ng/dL on two separate occasions. His luteinizing hormone is low-normal at 1.8 IU/L, indicating a central defect. His initial prolactin is 85 mcg/L, and a properly timed repeat test confirms a level of 88 mcg/L.
He takes no medications and has normal thyroid and kidney function. Because the hyperprolactinemia is persistent, unexplained, and accompanied by central hypogonadism, pituitary magnetic resonance imaging is ordered. The scan identifies a 6-millimeter microadenoma. Medical therapy with a dopamine agonist successfully lowers his prolactin, restoring luteinizing hormone signaling and normalizing his natural testosterone production without requiring lifelong hormone replacement.
A 45-year-old man undergoing a health checkup receives a lab report showing a total testosterone of 270 ng/dL and a prolactin level of 32 mcg/L, slightly above the laboratory reference limit of 20 mcg/L. His luteinizing hormone is within the mid-normal range. He reports intense anxiety during the blood draw, which required multiple needle sticks.
Rather than ordering an immediate brain scan, his physician schedules a repeat fasting test under calm conditions two weeks later. The repeat test shows a normal prolactin level of 12 mcg/L and a total testosterone of 360 ng/dL. The initial abnormal prolactin was an artifact of acute venipuncture stress, saving the patient from unnecessary imaging and worry.
A 52-year-old man taking a prescribed antipsychotic medication develops reduced sexual drive and low energy. Lab work confirms low total testosterone and low luteinizing hormone. His prolactin level is measured at 65 mcg/L.
A thorough review of his medical history indicates that the elevation aligns with his psychiatric pharmacotherapy. His clinician consults with his prescribing psychiatrist rather than stopping the medication abruptly. Because the medication cannot be safely altered, a pituitary scan is performed to rule out a concurrent mass, confirming drug-induced hyperprolactinemia as the primary mechanism behind his low testosterone.
A 34-year-old man with no sexual symptoms or fatigue undergoes hormone testing as part of a broad executive wellness panel. His total testosterone is healthy at 620 ng/dL, but his reported prolactin is flagged high at 48 mcg/L.
Given the complete absence of clinical symptoms or gonadotropin suppression, the laboratory performs polyethylene glycol precipitation to screen for macroprolactin. The test confirms that 85 percent of the circulating hormone consists of inactive macroprolactin complexes, with monomeric prolactin resting comfortably within the normal reference range. No further testing or medical intervention is required.
A 49-year-old man presents with profound lethargy, muscle loss, and loss of libido. Lab testing shows severe secondary hypogonadism, with a confirmed total testosterone of 110 ng/dL and an inappropriately low luteinizing hormone of 0.8 IU/L. However, his prolactin level is completely normal at 8 mcg/L.
Following established clinical guidance, his physician orders a pituitary magnetic resonance imaging scan despite the normal prolactin value, because his total testosterone is well below the 150 ng/dL threshold. The imaging reveals a 12-millimeter non-functioning pituitary macroadenoma that is mechanically compressing normal pituitary tissue. He is promptly referred to neurosurgery and neuroendocrinology for specialized care.
When evaluating scientific literature on prolactin and male hypogonadism, readers must distinguish between large-scale clinical consensus guidelines, controlled clinical trials, and observational cohort studies.
Clinical practice guidelines from bodies such as the American Urological Association, the Endocrine Society, and the European Association of Urology represent the highest level of synthesized evidence. These guidelines combine rigorous systematic reviews of diagnostic accuracy, clinical outcomes, and expert panel consensus. Recommendations regarding repeat testing, medication reviews, and imaging thresholds reflect decades of validated endocrine methodology.
Observational studies provide valuable real-world data but often reflect specific, pre-selected patient groups. For example, a published clinical study evaluated 3,101 men undergoing fertility evaluations. In this specific cohort, hyperprolactinemia was identified in 65 men, representing an overall prevalence of 2.1 percent.
Men with hyperprolactinemia in this study had significantly lower median total testosterone levels compared to men with normal prolactin (280 ng/dL versus 313 ng/dL). They also showed significantly lower total motile sperm counts (7.0 million versus 34.7 million) and higher rates of oligospermia (43.1 percent versus 21.5 percent). Among the 65 men with hyperprolactinemia, 11 were diagnosed with a prolactinoma, establishing an overall prolactinoma prevalence of 0.35 percent across the entire fertility cohort.
While these findings demonstrate the clear impact of excess prolactin on male reproductive health, the prevalence figures cannot be applied universally to all men with mild fatigue. Men attending a dedicated fertility clinic represent a specialized population with higher baseline rates of reproductive pathology than the general public.
Similarly, clinical studies investigating sexual function in men already diagnosed with pituitary tumors report high rates of endocrine disturbance. Research shows that testosterone deficiency occurs in roughly 73 percent of men with macroprolactinomas and 50 percent of men with microprolactinomas. Reductions in libido and sexual potency are reported by over half of these patients.
These figures confirm that prolactinomas significantly impair androgen production, but they do not suggest that pituitary tumors are common among all men with low testosterone. Understanding low testosterone causes and risk factors requires viewing prolactin as an important diagnostic checkpoint rather than an everyday explanation for non-specific symptoms.
Navigating hormone testing requires close collaboration with a knowledgeable healthcare provider, such as an endocrinologist or urologist. Approaching clinical appointments with focused questions helps ensure that all relevant factors are evaluated before making treatment decisions.
When reviewing hormone results, consider asking the following questions:
Clear communication with your medical team ensures that abnormal laboratory values are interpreted safely, accurately, and in the context of your overall health.
Interpreting prolactin within the full context of symptoms, repeat lab results, and gonadotropin signaling provides the safest and most reliable path to understanding male hormonal health.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
